RIPK3 and neoplasm: For instance, MLKL-mediated necroptosis releases CXCL5, which recruits MDSCs and suppresses T-cell activity while elevated RIPK3 expression drives an immunosuppressive microenvironment through CXCL1, thereby accelerating tumor progression [48–50].